Total Payments
$636,827
2024 Payments
$5,683
Companies
23
Transactions
648
Medicare Patients
491
Medicare Billing
$51,149
Payment Breakdown by Category
Other$363,731 (57.1%)
Consulting$178,620 (28.0%)
Travel$50,728 (8.0%)
Research$29,410 (4.6%)
Food & Beverage$14,233 (2.2%)
Education$104.77 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $358,231 | 152 | 56.3% |
| Consulting Fee | $178,620 | 62 | 28.0% |
| Travel and Lodging | $50,728 | 162 | 8.0% |
| Unspecified | $29,410 | 10 | 4.6% |
| Food and Beverage | $14,233 | 256 | 2.2% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,000 | 1 | 0.5% |
| Grant | $2,500 | 1 | 0.4% |
| Education | $104.77 | 4 | 0.0% |
Payments by Type
General
$607,417
638 transactions
Research
$29,410
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $222,814 | 340 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $138,900 | 78 | $0 (2019) |
| Novo Nordisk Inc | $67,558 | 39 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $62,385 | 45 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $35,313 | 51 | $0 (2019) |
| Novo Nordisk AS | $26,325 | 4 | $0 (2023) |
| Esperion Therapeutics, Inc. | $23,635 | 15 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $17,409 | 19 | $0 (2019) |
| Merck Sharp & Dohme LLC | $14,846 | 28 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $7,280 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,683 | 20 | Amgen Inc. ($5,101) |
| 2023 | $25,788 | 35 | Amgen Inc. ($15,297) |
| 2022 | $7,489 | 25 | Amgen Inc. ($7,091) |
| 2021 | $36,851 | 45 | Esperion Therapeutics, Inc. ($20,577) |
| 2020 | $74,021 | 47 | Novo Nordisk AS ($21,600) |
| 2019 | $184,216 | 172 | SANOFI-AVENTIS U.S. LLC ($67,653) |
| 2018 | $123,270 | 105 | SANOFI-AVENTIS U.S. LLC ($40,647) |
| 2017 | $179,508 | 199 | Amgen Inc. ($80,227) |
All Payment Transactions
648 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Cardiology | ||||||
| 11/14/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $11.20 | General |
| Category: Cardiology | ||||||
| 10/25/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Cardiology | ||||||
| 10/15/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 10/15/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,868.00 | General |
| Category: Cardiology | ||||||
| 10/10/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $133.16 | General |
| Category: Cardiology | ||||||
| 10/04/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Cardiology | ||||||
| 09/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 08/22/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: Cardiology | ||||||
| 08/09/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $48.97 | General |
| Category: Coronary | ||||||
| 08/08/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: Cardiology | ||||||
| 07/19/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Cardiology | ||||||
| 06/20/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $117.98 | General |
| Category: Cardiology | ||||||
| 05/24/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $50.19 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/23/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: Cardiology | ||||||
| 05/10/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $32.57 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 05/09/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Cardiology | ||||||
| 04/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Cardiology | ||||||
| 03/07/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: Cardiology | ||||||
| 01/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Cardiology | ||||||
| 11/22/2023 | Amgen Inc. | Repatha (Biological) | Travel and Lodging | Cash or cash equivalent | $209.64 | General |
| Category: Cardiology | ||||||
| 11/22/2023 | Amgen Inc. | Repatha (Biological) | Travel and Lodging | Cash or cash equivalent | $102.40 | General |
| Category: Cardiology | ||||||
| 11/15/2023 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 11/15/2023 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,868.00 | General |
| Category: Cardiology | ||||||
| 11/09/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $103.76 | General |
| Category: Cardiology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EX6018-4758 | Novo Nordisk AS | $21,600 | 2 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $7,486 | 7 |
| in kind shipment 13 Apr 2023 | Dexcom, Inc. | $324.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 146 | 171 | $66,201 | $14,886 |
| 2022 | 3 | 151 | 175 | $66,005 | $15,248 |
| 2021 | 3 | 102 | 132 | $48,878 | $12,452 |
| 2020 | 3 | 92 | 108 | $39,961 | $8,563 |
Total Patients
491
Total Services
586
Medicare Billing
$51,149
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 75 | 96 | $40,700 | $9,232 | 22.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 49 | $14,217 | $3,262 | 22.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 26 | 26 | $11,284 | $2,392 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 89 | 108 | $44,408 | $10,667 | 24.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 41 | 46 | $12,802 | $2,790 | 21.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 21 | 21 | $8,795 | $1,790 | 20.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 65 | 90 | $35,580 | $9,103 | 25.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 22 | 27 | $7,277 | $2,067 | 28.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 15 | 15 | $6,021 | $1,282 | 21.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 67 | 82 | $31,284 | $6,589 | 21.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 12 | 12 | $5,025 | $1,129 | 22.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 13 | 14 | $3,652 | $845.93 | 23.2% |
About Michael Davidson
Michael Davidson is a Cardiovascular Disease healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023033321.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Davidson has received a total of $636,827 in payments from pharmaceutical and medical device companies, with $5,683 received in 2024. These payments were reported across 648 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($358,231).
As a Medicare-enrolled provider, Davidson has provided services to 491 Medicare beneficiaries, totaling 586 services with total Medicare billing of $51,149. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Chicago, IL
- Active Since 07/13/2006
- Last Updated 10/24/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1023033321
Products in Payments
- Repatha (Biological) $215,147
- PRALUENT (Drug) $101,617
- EPANOVA (Drug) $49,825
- NO PRODUCT DISCUSSED (Drug) $37,283
- Victoza (Drug) $32,174
- PRALUENT ALIROCUMAB INJECTION (Biological) $27,825
- PRALUENT (Biological) $24,898
- NEXLIZET (Drug) $21,802
- FARXIGA (Drug) $14,614
- JARDIANCE (Drug) $11,805
- Ozempic (Drug) $9,753
- Tresiba (Drug) $5,518
- MK0859 (Drug) $4,150
- NEXLETOL (Drug) $1,833
- DEXCOM G7 GSS (161) (Medical Supply) $324.00
- Corlanor (Drug) $152.50
- KYNAMRO (Drug) $119.66
- LEQVIO (Drug) $118.75
- Vascepa (Drug) $113.48
- MK-0859 (Drug) $64.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Chicago
Sandeep Nathan
Cardiovascular Disease — Payments: $950,057
Cardiovascular Disease $950,057
Jonathan Rich, M.d, M.D
Cardiovascular Disease — Payments: $597,351
Cardiovascular Disease $597,351
Sanjiv Shah, Md, MD
Cardiovascular Disease — Payments: $448,175
Cardiovascular Disease $448,175
Boaz Avitall
Cardiovascular Disease — Payments: $337,061
Cardiovascular Disease $337,061
Daniel Fintel, Md, MD
Cardiovascular Disease — Payments: $254,863
Cardiovascular Disease $254,863
Adhir Shroff, M.d, M.D
Cardiovascular Disease — Payments: $231,800
Cardiovascular Disease $231,800